Dicerna Pharmaceuticals
DRNADicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) was a biotechnology company based in the United States. Its core business was the discovery and development of ribonucleic acid interference (RNAi) therapeutics. The company's operations were centered on its proprietary GalXC™ RNAi platform technology, which was designed to enable the development of subcutaneously administered RNAi therapies that selectively silence disease-driving genes in the liver. The company's research and development pipeline targeted diseases with genetic drivers, primarily focusing on rare, cardiometabolic, viral infectious, and chronic liver diseases. Dicerna's most advanced investigational candidate was nedosiran, an RNAi therapeutic designed for the treatment of primary hyperoxaluria. The company also had clinical-stage programs targeting cardiovascular disease and had collaborative research initiatives in areas including chronic hepatitis B and alpha-1 antitrypsin deficiency-associated liver disease. In December 2021, Dicerna Pharmaceuticals was acquired by Novo Nordisk A/S. Consequently, its stock was delisted from the Nasdaq, and it now operates as a wholly-owned subsidiary, integrating its RNAi platform technology into Novo Nordisk's research and development efforts.
About
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) was a biotechnology company based in the United States. Its core business was the discovery and development of ribonucleic acid interference (RNAi) therapeutics. The company's operations were centered on its proprietary GalXC™ RNAi platform technology, which was designed to enable the development of subcutaneously administered RNAi therapies that selectively silence disease-driving genes in the liver. The company's research and development pipeline targeted diseases with genetic drivers, primarily focusing on rare, cardiometabolic, viral infectious, and chronic liver diseases. Dicerna's most advanced investigational candidate was nedosiran, an RNAi therapeutic designed for the treatment of primary hyperoxaluria. The company also had clinical-stage programs targeting cardiovascular disease and had collaborative research initiatives in areas including chronic hepatitis B and alpha-1 antitrypsin deficiency-associated liver disease. In December 2021, Dicerna Pharmaceuticals was acquired by Novo Nordisk A/S. Consequently, its stock was delisted from the Nasdaq, and it now operates as a wholly-owned subsidiary, integrating its RNAi platform technology into Novo Nordisk's research and development efforts.